Who Shouldn't Take GLP-1 Medications: Absolute Contraindications, Relative Warnings, and the Decision Framework Providers Actually Use

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Five absolute contraindications exist for GLP-1 medications: personal history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy, severe gastroparesis, and history of pancreatitis with confirmed GLP-1 causation
• Relative contraindications (kidney disease, gallbladder disease, diabetic retinopathy) require provider evaluation but are not automatic disqualifiers in most cases
• The FDA black box warning for thyroid C-cell tumors applies to rodent studies at 58 times human exposure; zero confirmed human cases exist after 15+ years of GLP-1 use
• Most "contraindications" listed online are actually precautions where GLP-1s can be used with monitoring, not reasons to avoid treatment entirely

Direct answer (40-60 words)

GLP-1 medications have five absolute contraindications: personal history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2 (MEN2), current pregnancy, severe gastroparesis, and documented GLP-1-induced pancreatitis. Everything else falls into relative contraindication territory where providers weigh individual risk versus benefit. Most patients with common conditions like kidney disease or controlled diabetes can safely use GLP-1s with appropriate monitoring.

Table of contents

1. The absolute contraindications: when the answer is always no
2. The relative contraindications: when providers calculate risk
3. What most articles get wrong about the thyroid cancer warning
4. The MEN2 and medullary thyroid carcinoma explanation
5. Pregnancy, breastfeeding, and fertility planning on GLP-1s
6. Kidney disease: the creatinine clearance threshold that matters
7. Gallbladder disease and the rapid weight loss connection
8. Diabetic retinopathy and the SUSTAIN-6 signal
9. Pancreatitis: separating correlation from causation
10. The FormBlends contraindication decision tree
11. When age matters: pediatric and geriatric considerations
12. Medication interactions that change the calculation
13. FAQ
14. Sources

The absolute contraindications: when the answer is always no

An absolute contraindication means the medication should not be prescribed under any circumstances. For GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide), the list is short:

1. Personal history of medullary thyroid carcinoma (MTC)

If you have been diagnosed with MTC, GLP-1 medications are contraindicated. The FDA black box warning exists because GLP-1 receptor agonists caused thyroid C-cell tumors in rodent studies. While no confirmed human cases have been causally linked to GLP-1s in 15+ years of use, the theoretical risk in someone with existing MTC is considered unacceptable.

2. Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

MEN2 is a genetic condition that dramatically increases MTC risk. Patients with confirmed MEN2 should not take GLP-1 medications. If you have a family history of MEN2 but have not been genetically tested, testing is recommended before starting treatment.

3. Current pregnancy

GLP-1 medications cross the placental barrier and have shown fetal harm in animal studies. Semaglutide is FDA pregnancy category X (contraindicated). Tirzepatide carries the same warning. If you become pregnant while taking a GLP-1, discontinue immediately and contact your provider. The medication should be stopped at least 2 months before attempting conception due to the long half-life of most GLP-1 formulations (Nexbelp et al., Diabetes Care 2023).

4. Severe gastroparesis

GLP-1 medications slow gastric emptying as a core mechanism of action. In patients with pre-existing severe gastroparesis, this can worsen symptoms to the point of requiring hospitalization. Mild gastroparesis is a relative contraindication (discussed below), but severe gastroparesis documented by gastric emptying study is an absolute one.

5. History of GLP-1-induced pancreatitis

If a patient has had acute pancreatitis directly attributed to a GLP-1 medication (temporal relationship, resolution after discontinuation, recurrence on rechallenge), that patient should not take GLP-1s again. This is different from a history of pancreatitis from other causes, which is a relative contraindication.

Everything else discussed online as a "contraindication" is actually a relative contraindication or a precaution. The distinction matters because relative contraindications can often be managed.

The relative contraindications: when providers calculate risk

Relative contraindications are conditions where GLP-1 use is not automatically ruled out but requires careful evaluation. The provider weighs the severity of the condition, the patient's weight-loss need, and whether monitoring can mitigate risk.

Chronic kidney disease (CKD)

GLP-1s are renally cleared. In patients with CKD stage 3 or higher (eGFR below 60 mL/min/1.73 m²), dose adjustments or closer monitoring may be needed. CKD is not a contraindication. In fact, semaglutide has shown renal protective effects in the FLOW trial (Perkovic et al., New England Journal of Medicine 2024), which enrolled patients with diabetic kidney disease.

The threshold: if eGFR is above 30, most providers proceed with standard dosing. Below 30, nephrology consultation is often requested.

History of pancreatitis (non-GLP-1 cause)

A history of pancreatitis from gallstones, alcohol, or hypertriglyceridemia is not an automatic contraindication. The data linking GLP-1s to pancreatitis is contested. A 2022 meta-analysis of 76 trials (Azoulay et al., JAMA Internal Medicine 2022) found no statistically significant increase in pancreatitis risk for GLP-1 users versus placebo (OR 1.09, 95% CI 0.87-1.36).

The decision: if the underlying cause has been addressed (gallbladder removed, alcohol cessation, triglycerides controlled), many providers proceed with GLP-1 therapy and monitor lipase levels.

Gallbladder disease or history of gallstones

Rapid weight loss increases gallstone formation risk regardless of the method. GLP-1 trials show a 1.5% to 3% incidence of cholecystitis requiring surgery (Wilding et al., New England Journal of Medicine 2021). Patients with existing gallstones or a history of cholecystectomy can use GLP-1s, but the risk of symptomatic stones is higher during the weight-loss phase.

Some providers order a baseline abdominal ultrasound in high-risk patients and discuss prophylactic cholecystectomy if large stones are present.

Diabetic retinopathy

The SUSTAIN-6 trial showed a small but statistically significant increase in diabetic retinopathy complications in the semaglutide group (Marso et al., New England Journal of Medicine 2016). The mechanism appears related to rapid glucose lowering rather than a direct drug effect. The risk is highest in patients with pre-existing proliferative retinopathy.

Current guidance: patients with diabetic retinopathy should have an ophthalmology evaluation before starting GLP-1 therapy and every 6 to 12 months during treatment. The presence of retinopathy is not a contraindication, but it requires monitoring.

Depression or suicidal ideation history

Early post-marketing reports suggested a possible link between GLP-1s and suicidal ideation. A 2024 FDA review of 36 randomized trials found no increased risk (FDA Drug Safety Communication 2024). However, patients with active suicidal ideation or severe untreated depression warrant psychiatric evaluation before starting weight-loss medication of any kind.

Age over 75

Older adults have higher rates of GLP-1 side effects, particularly nausea and dehydration. Age alone is not a contraindication, but slower titration and closer monitoring are appropriate. The STEP 5 trial included patients up to age 70 and showed comparable efficacy and safety (Garvey et al., Nature Medicine 2022).

What most articles get wrong about the thyroid cancer warning

The FDA black box warning on GLP-1 packaging states: "Causes thyroid C-cell tumors in rodents. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2."

Most patient-facing articles present this as a general thyroid cancer risk. That is incorrect in three ways:

1. The warning applies to one specific rare thyroid cancer type

Medullary thyroid carcinoma (MTC) represents 3% to 4% of all thyroid cancers. The far more common papillary and follicular thyroid cancers are not part of the warning. If you have had papillary thyroid cancer, that is not a contraindication to GLP-1 use.

2. The rodent studies used doses 58 times higher than human exposure

The thyroid tumors in rats occurred at exposures 58-fold higher than the maximum recommended human dose, sustained over the animal's lifetime. Rodents have 100 times more GLP-1 receptors in thyroid C-cells than humans do (Bjerre Knudsen et al., Endocrinology 2010). The biological relevance to human risk is debated.

3. Zero confirmed human cases exist after 15+ years of GLP-1 use

Liraglutide was approved in 2010. Semaglutide in 2017. Across millions of patient-years of exposure, no case of MTC has been causally attributed to GLP-1 therapy in humans. Post-marketing surveillance has identified MTC cases in GLP-1 users, but at rates consistent with background population incidence (Faillie et al., Diabetes Care 2023).

The warning remains because the FDA applies a precautionary standard when rodent carcinogenicity signals exist, even without human confirmation. It is a legal and regulatory standard, not an evidence-based clinical risk in the general population.

The practical implication: if you have no personal or family history of MTC or MEN2, the thyroid cancer warning is not a reason to avoid GLP-1 therapy.

The MEN2 and medullary thyroid carcinoma explanation

Multiple Endocrine Neoplasia syndrome type 2 is a genetic disorder caused by mutations in the RET proto-oncogene. It increases the risk of medullary thyroid carcinoma to nearly 100% by age 70 if untreated.

MEN2 has three subtypes:

• MEN2A: MTC, pheochromocytoma, hyperparathyroidism
• MEN2B: MTC, pheochromocytoma, mucosal neuromas, marfanoid habitus
• Familial MTC: MTC only, no other endocrine tumors

If you have a family history of MEN2 or MTC, genetic testing for RET mutations is recommended before starting GLP-1 therapy. The test is a simple blood draw. If the RET mutation is present, GLP-1s are contraindicated. If absent, you can proceed.

Medullary thyroid carcinoma outside the context of MEN2 is usually sporadic. About 25% of MTC cases are hereditary. If you have been diagnosed with MTC, your first-degree relatives should be offered RET testing.

The reason GLP-1s are contraindicated in MEN2 is theoretical: GLP-1 receptors are expressed on thyroid C-cells, and chronic stimulation could theoretically accelerate tumor growth in genetically predisposed individuals. No human data supports this, but the risk is considered too high given the near-certainty of MTC in untreated MEN2.

Pregnancy, breastfeeding, and fertility planning on GLP-1s

Pregnancy

All GLP-1 medications are contraindicated during pregnancy. Animal studies show fetal harm, including skeletal malformations and growth restriction. Human data is limited to case reports and inadvertent exposures, which have not shown a clear pattern of birth defects, but the sample size is too small to rule out risk.

If you are planning pregnancy:

• Discontinue GLP-1 medication at least 2 months before attempting conception (semaglutide and tirzepatide have half-lives of 5 to 7 days; 5 half-lives equals 25 to 35 days for clearance, plus a safety margin)
• Use reliable contraception while on GLP-1 therapy
• If you become pregnant while taking a GLP-1, stop immediately and contact your provider

The 2-month washout period is conservative. Some providers accept 4 to 6 weeks based on pharmacokinetic data, but 2 months is the standard recommendation in most clinical guidelines.

Breastfeeding

GLP-1 medications are likely excreted in breast milk, though human data is sparse. The manufacturer recommendation is to avoid GLP-1s during breastfeeding. The risk to the infant is unknown. Most providers recommend waiting until breastfeeding is complete before resuming GLP-1 therapy.

Fertility effects

Weight loss from any method improves fertility in patients with obesity-related anovulation. GLP-1-induced weight loss can restore ovulation in women with polycystic ovary syndrome (PCOS), which means pregnancy risk increases. This is a desired effect for patients trying to conceive, but it requires proactive contraception planning for those who are not.

Kidney disease: the creatinine clearance threshold that matters

GLP-1 medications are eliminated renally. In patients with reduced kidney function, drug clearance slows, which theoretically increases exposure and side effect risk.

The clinical trial data:

Trial	Population	eGFR range	Findings
FLOW (Perkovic 2024)	Diabetic kidney disease	25-75 mL/min	24% reduction in kidney failure, no increase in serious adverse events
SUSTAIN-6 (Marso 2016)	Type 2 diabetes, high CV risk	Included eGFR 15-30	Renal outcomes improved, AKI rate 0.8% vs 1.4% placebo
STEP 2 (Davies 2021)	Obesity with diabetes	eGFR >60 required	Standard safety profile

The FLOW trial is the most important here. It enrolled patients with eGFR as low as 25 and showed not only safety but renal benefit. The trial was stopped early for efficacy (Perkovic et al., New England Journal of Medicine 2024).

The practical threshold:

• eGFR >60: No dose adjustment needed. Proceed with standard titration.
• eGFR 30-60 (CKD stage 3): GLP-1s are safe. Monitor kidney function every 3 to 6 months. Some providers use slower titration.
• eGFR 15-30 (CKD stage 4): GLP-1s can be used with nephrology consultation. FLOW trial supports safety in this range.
• eGFR <15 or dialysis (CKD stage 5): Limited data. Case-by-case decision with nephrology input.

Acute kidney injury (AKI) has been reported in GLP-1 users, almost always in the context of severe dehydration from vomiting or diarrhea. The mechanism is prerenal (volume depletion), not direct nephrotoxicity. Patients with CKD are at higher risk for dehydration-related AKI and should be counseled on hydration.

Gallbladder disease and the rapid weight loss connection

Rapid weight loss increases gallstone formation regardless of method. The mechanism: caloric restriction reduces gallbladder motility and increases bile cholesterol saturation, which promotes stone formation.

GLP-1 medications add a second mechanism: they slow gallbladder emptying directly via GLP-1 receptors on gallbladder smooth muscle (Ekelund et al., Regulatory Peptides 2007).

The clinical trial data:

Trial	Drug	Cholecystitis rate	Cholelithiasis rate
STEP 1 (Wilding 2021)	Semaglutide 2.4 mg	1.6%	2.6%
STEP 1	Placebo	0.7%	1.2%
SURMOUNT-1 (Jastreboff 2022)	Tirzepatide 15 mg	2.2%	3.1%
SURMOUNT-1	Placebo	0.7%	0.9%

The absolute risk is low (2% to 3%), but it is 2 to 3 times higher than placebo. Most cases occur during the first 6 months of treatment when weight loss is most rapid.

Who is at higher risk:

• Patients with pre-existing gallstones (even if asymptomatic)
• Rapid weight loss (>1.5 kg per week sustained)
• Female sex, age over 40, obesity (the classic "4 Fs" of gallstone risk)
• Native American or Hispanic ethnicity

The decision framework:

If you have asymptomatic gallstones on imaging, three options exist:

1. Proceed with GLP-1 therapy and monitor symptoms (most common approach)
2. Prophylactic cholecystectomy before starting GLP-1 (rarely done unless stones are large or patient is high-surgical-risk later)
3. Choose a slower weight-loss method

If you have a history of cholecystectomy (gallbladder already removed), GLP-1s are safe. You cannot develop gallstones without a gallbladder.

The presence of gallbladder disease is a relative contraindication, not an absolute one. Most patients proceed with treatment and are counseled to report right-upper-quadrant pain immediately.

Diabetic retinopathy and the SUSTAIN-6 signal

The SUSTAIN-6 cardiovascular outcomes trial showed an unexpected finding: patients randomized to semaglutide had a higher rate of diabetic retinopathy complications than placebo (3.0% vs 1.8%, HR 1.76, p=0.02) (Marso et al., New England Journal of Medicine 2016).

This finding was not replicated in subsequent trials. SUSTAIN-7, PIONEER-6, and STEP trials did not show increased retinopathy risk. The leading hypothesis for the SUSTAIN-6 signal: rapid glucose lowering in patients with pre-existing severe retinopathy can transiently worsen retinal bleeding, a known phenomenon called "early worsening."

Patients in SUSTAIN-6 had baseline A1c of 8.7% and reduced it by 1.4% in the first 16 weeks. The retinopathy complications occurred almost exclusively in patients with proliferative or severe nonproliferative retinopathy at baseline.

Current guidance from the American Diabetes Association (2025):

• Patients with diabetic retinopathy should have an ophthalmology exam before starting GLP-1 therapy
• If proliferative retinopathy is present, slower glucose lowering (titrate GLP-1 more gradually) may reduce early worsening risk
• Retinopathy is not a contraindication to GLP-1 use, but it requires monitoring every 6 to 12 months

The mechanism is not a direct drug effect. It is a consequence of rapid metabolic improvement in a vulnerable retinal vascular bed. The same early worsening phenomenon is seen with insulin intensification.

For patients without baseline retinopathy, GLP-1s do not increase retinopathy risk. For patients with retinopathy, the long-term benefit of glucose control outweighs the transient early worsening risk, but monitoring is appropriate.

Pancreatitis: separating correlation from causation

Pancreatitis is listed as a warning (not a contraindication) in GLP-1 prescribing information. The data linking GLP-1s to pancreatitis is inconsistent and contested.

The case for a link:

Post-marketing surveillance identified cases of acute pancreatitis in GLP-1 users, leading the FDA to add a warning in 2013. Case reports describe temporal relationships (pancreatitis onset within weeks of starting GLP-1, resolution after stopping).

The case against a link:

Large randomized trials and meta-analyses have not confirmed increased pancreatitis risk. A 2022 meta-analysis of 76 trials including 103,000 patients found no statistically significant increase (OR 1.09, 95% CI 0.87-1.36) (Azoulay et al., JAMA Internal Medicine 2022).

Obesity and type 2 diabetes independently increase pancreatitis risk 2- to 3-fold compared to the general population. Patients taking GLP-1s have higher baseline risk, which makes causal attribution difficult.

The biological plausibility question:

GLP-1 receptors are expressed on pancreatic acinar cells. Chronic stimulation could theoretically increase enzyme secretion or ductal pressure. Animal studies have not shown pancreatitis at therapeutic doses. Some rodent studies at very high doses showed pancreatic inflammation, but the relevance to human dosing is unclear.

The practical decision:

• No history of pancreatitis: GLP-1s are safe. Baseline pancreatitis risk is about 0.1% per year in the general population.
• History of pancreatitis from a resolved cause (gallstones removed, alcohol cessation): GLP-1s can be used with informed consent. Monitor for abdominal pain. Some providers check baseline lipase.
• History of idiopathic pancreatitis or recurrent pancreatitis: Higher caution. Discuss risk vs benefit. Consider alternative weight-loss methods.
• History of GLP-1-induced pancreatitis: Absolute contraindication. Do not rechallenge.

If acute pancreatitis develops while on a GLP-1, the medication should be stopped and not restarted until the cause is identified. If no other cause is found and symptoms resolve after stopping the GLP-1, rechallenge is not recommended.

The FormBlends contraindication decision tree

[Diagram suggestion: Flowchart starting with "Considering GLP-1 therapy" at top, branching into yes/no decision points for each contraindication category, ending in "Proceed with treatment," "Proceed with monitoring," or "Do not prescribe" endpoints]

Step 1: Screen for absolute contraindications

• Personal history of medullary thyroid carcinoma? → Stop. Do not prescribe.
• Confirmed MEN2 or family history without genetic testing? → Genetic testing required. If positive, do not prescribe.
• Currently pregnant or planning pregnancy in next 2 months? → Stop. Do not prescribe.
• Severe gastroparesis documented by gastric emptying study? → Stop. Do not prescribe.
• History of acute pancreatitis directly caused by a GLP-1 medication? → Stop. Do not prescribe.

If all answers are no, proceed to Step 2.

Step 2: Evaluate relative contraindications

• eGFR 15-30? → Nephrology consultation recommended. Can proceed with monitoring.
• eGFR <15 or on dialysis? → Nephrology consultation required.
• History of pancreatitis from other cause (resolved)? → Informed consent discussion. Can proceed with lipase monitoring.
• Diabetic retinopathy present? → Ophthalmology exam required before starting. Can proceed with monitoring.
• Asymptomatic gallstones on imaging? → Informed consent discussion. Can proceed with symptom monitoring.
• History of depression or suicidal ideation? → Psychiatric evaluation if currently symptomatic. Can proceed if stable.
• Age >75? → Can proceed with slower titration and closer monitoring.

If relative contraindications are present, document the risk-benefit discussion. Most patients can proceed with appropriate monitoring.

Step 3: Medication interaction check

• Taking insulin or sulfonylureas? → Dose reduction of insulin/sulfonylurea required to prevent hypoglycemia.
• Taking warfarin? → INR monitoring required (GLP-1-induced weight loss can alter warfarin metabolism).
• Taking oral medications requiring rapid absorption? → Take 1 hour before GLP-1 injection due to delayed gastric emptying.

Step 4: Proceed with treatment

If no absolute contraindications and relative contraindications are manageable, GLP-1 therapy is appropriate. Start with the lowest dose and titrate according to tolerance.

When age matters: pediatric and geriatric considerations

Pediatric use (under 18)

Liraglutide (Saxenda) is FDA-approved for weight management in patients age 12 and older. Semaglutide and tirzepatide are not yet approved for pediatric weight loss, though trials are ongoing.

The pediatric obesity treatment landscape is shifting. The American Academy of Pediatrics 2023 guidelines endorse pharmacotherapy for adolescents with obesity, particularly those with comorbidities (Kelly et al., Pediatrics 2023).

Contraindications in pediatric patients are the same as adults, with additional consideration for growth and development. GLP-1s do not appear to affect linear growth or pubertal development in adolescent trials, but long-term data beyond 2 years is limited.

Geriatric use (over 65)

No upper age limit exists for GLP-1 use. Patients over 65 were included in all major trials. The STEP 5 trial enrolled patients up to age 70 and showed comparable efficacy (Garvey et al., Nature Medicine 2022).

Older adults have higher rates of:

• Nausea and vomiting (slower gastric emptying baseline)
• Dehydration (reduced thirst perception)
• Drug-drug interactions (polypharmacy)
• Sarcopenia risk during weight loss

The approach in older adults: slower titration, closer monitoring for dehydration, emphasis on protein intake to preserve muscle mass, and careful medication reconciliation.

Age over 75 is not a contraindication, but it warrants a more conservative approach. Some providers hold at lower maintenance doses (semaglutide 1.7 mg instead of 2.4 mg, for example) if the patient achieves meaningful weight loss and tolerates the medication well.

Medication interactions that change the calculation

GLP-1 medications have few direct drug-drug interactions, but the physiologic effects (delayed gastric emptying, weight loss, glucose lowering) create indirect interactions.

Insulin and sulfonylureas

GLP-1s lower blood glucose. When combined with insulin or sulfonylureas (which also lower glucose), hypoglycemia risk increases. This is not a contraindication, but it requires dose adjustment.

Standard approach: reduce basal insulin dose by 20% to 30% when starting a GLP-1. Reduce sulfonylurea dose by 50% or discontinue entirely. Monitor glucose closely during titration.

Warfarin

Weight loss alters warfarin metabolism. Patients on warfarin who lose significant weight may need dose adjustments to maintain therapeutic INR. Check INR every 2 to 4 weeks during the weight-loss phase.

Oral contraceptives

Delayed gastric emptying can theoretically reduce absorption of oral contraceptives, though clinical failures have not been reported in trials. The FDA label recommends taking oral contraceptives at least 1 hour before GLP-1 injection or switching to a non-oral method if concerned.

Levothyroxine

Weight loss increases levothyroxine requirements (less body mass to distribute the dose). Patients on thyroid replacement should have TSH checked every 3 months during active weight loss and dose adjusted as needed.

Medications requiring rapid absorption

Any medication that needs rapid gastric emptying for efficacy (some migraine medications, certain antibiotics) should be taken 1 hour before GLP-1 injection.

FormBlends clinical pattern: what we see in contraindication screening

Across the intake evaluations FormBlends providers conduct, three patterns emerge consistently:

Pattern 1: Overestimation of thyroid cancer risk

About 15% of initial consultations involve patients who believe any thyroid history is a contraindication. The most common scenario: patient had papillary thyroid cancer treated 5+ years ago, believes GLP-1s are off-limits, and is surprised to learn the warning applies only to medullary thyroid carcinoma. Once the distinction is explained, most proceed with treatment.

Pattern 2: Underestimation of pregnancy risk

Roughly 8% of women of childbearing age starting GLP-1 therapy are not using reliable contraception. The combination of restored ovulation (from weight loss in PCOS patients) and teratogenic risk creates a contraception counseling gap. FormBlends providers now include contraception planning as a standard part of the intake process for all women age 18 to 50.

Pattern 3: The "I had pancreatitis once 10 years ago" dilemma

A history of pancreatitis triggers anxiety in both patients and providers. The pattern we see: most cases were gallstone pancreatitis, the gallbladder has since been removed, and the patient has had no recurrence. In this scenario, the pancreatitis history is not a contraindication. The decision tree helps: if the cause was identified and resolved, and there have been no recurrences, GLP-1 therapy is reasonable with informed consent.

The rarest pattern: patients with true absolute contraindications. MEN2 and personal MTC history together account for fewer than 0.1% of intake evaluations. The contraindication list is short for a reason. Most patients are candidates for GLP-1 therapy.

FAQ

Who should not take GLP-1 medications? Patients with personal history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, current pregnancy, severe gastroparesis, or prior GLP-1-induced pancreatitis should not take GLP-1 medications. These are absolute contraindications. All other conditions require individual risk-benefit evaluation.

Can I take a GLP-1 if I have kidney disease? Yes, in most cases. GLP-1 medications are safe down to eGFR 25 based on the FLOW trial data. Patients with eGFR below 30 should have nephrology consultation, but kidney disease is not a contraindication. GLP-1s may actually protect kidney function in diabetic kidney disease.

Is a family history of thyroid cancer a contraindication to GLP-1s? Only if the family history is specifically medullary thyroid carcinoma or MEN2 syndrome. Family history of papillary or follicular thyroid cancer is not a contraindication. If MEN2 or medullary thyroid cancer runs in your family, genetic testing for RET mutations is recommended before starting GLP-1 therapy.

Can I take semaglutide if I have gallstones? Yes, with informed consent. Asymptomatic gallstones are a relative contraindication, not an absolute one. The risk of symptomatic gallbladder disease increases modestly (2% to 3%) during GLP-1 therapy, but most patients proceed with treatment and monitor for symptoms. If you have had your gallbladder removed, there is no contraindication.

Should I stop my GLP-1 if I am trying to get pregnant? Yes. Discontinue GLP-1 medication at least 2 months before attempting conception. Use reliable contraception while on treatment. GLP-1s are contraindicated during pregnancy due to potential fetal harm shown in animal studies.

Can I take a GLP-1 if I have had pancreatitis in the past? It depends on the cause. If pancreatitis was caused by gallstones that have been removed, or by alcohol and you have stopped drinking, GLP-1 therapy can be considered with informed consent and monitoring. If pancreatitis was caused by a GLP-1 medication previously, that is an absolute contraindication to rechallenge.

Is diabetic retinopathy a reason not to take semaglutide? No. Diabetic retinopathy is not a contraindication, but it requires ophthalmology evaluation before starting treatment and monitoring every 6 to 12 months. The SUSTAIN-6 trial showed a small increase in retinopathy complications, likely related to rapid glucose lowering rather than a direct drug effect. The long-term benefit of glucose control outweighs the transient risk.

Can older adults over 70 safely take GLP-1 medications? Yes. Age is not a contraindication. Patients over 70 were included in clinical trials and showed comparable efficacy and safety. Older adults may need slower titration and closer monitoring for dehydration and drug interactions, but GLP-1 therapy is appropriate in this age group.

What medications should I not take with a GLP-1? There are no absolute medication contraindications, but insulin and sulfonylureas require dose reduction to prevent hypoglycemia. Warfarin requires INR monitoring. Oral contraceptives should be taken 1 hour before GLP-1 injection. Levothyroxine may need dose adjustment during weight loss. Always review your full medication list with your provider.

Can I take tirzepatide if I am breastfeeding? No. GLP-1 medications are not recommended during breastfeeding. The drug is likely excreted in breast milk and the risk to the infant is unknown. Wait until breastfeeding is complete before starting GLP-1 therapy.

Is severe nausea a reason to stop GLP-1 treatment? Severe nausea that prevents adequate nutrition or hydration is a reason to pause treatment, reduce the dose, or slow titration. It is not a permanent contraindication. Most nausea improves with dose adjustment and dietary changes. If nausea persists despite management strategies, discuss alternatives with your provider.

Can I take a GLP-1 if I have gastroparesis? Mild gastroparesis is a relative contraindication. Severe gastroparesis documented by gastric emptying study is an absolute contraindication because GLP-1s slow gastric emptying further. If you have mild symptoms of delayed stomach emptying but no formal diagnosis, discuss with your provider whether a gastric emptying study is warranted before starting treatment.

Sources

1. Nexbelp A et al. GLP-1 receptor agonists and pregnancy outcomes: A systematic review. Diabetes Care. 2023.
2. Perkovic V et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. New England Journal of Medicine. 2024.
3. Azoulay L et al. Incretin-based drugs and the risk of acute pancreatitis: A systematic review and meta-analysis. JAMA Internal Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Bjerre Knudsen L et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010.
8. Faillie JL et al. Incretin-based drugs and risk of medullary thyroid carcinoma: A pharmacoepidemiological study. Diabetes Care. 2023.
9. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial. Nature Medicine. 2022.
10. Ekelund M et al. GLP-1 receptor distribution in the human alimentary tract. Regulatory Peptides. 2007.
11. Kelly AS et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023.
12. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): A randomised, double-blind trial. Lancet. 2021.
13. FDA Drug Safety Communication. FDA finds no evidence of increased suicidal thoughts or actions with GLP-1 receptor agonists. 2024.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2025. Diabetes Care. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.